NCT02457078

Brief Summary

This project will investigate whether adding nutritional supplements to the diet will have beneficial effects on the development of infant brain networks (assessed at 4 and 9 months of age). The nutritional supplement will contain lutein (typically found in leafy vegetables),docosahexaenoic acid (DHA; a fatty acid typically found in cold-water fish such as salmon or tuna), and of vitamin E.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Feb 2015

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

February 5, 2015

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 29, 2015

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

May 4, 2017

Status Verified

May 1, 2017

Enrollment Period

3.8 years

First QC Date

February 5, 2015

Last Update Submit

May 1, 2017

Conditions

Keywords

nutritional supplementsluteinDHAvitamin Einfant brain development

Outcome Measures

Primary Outcomes (2)

  • Brain Imaging (Event-Related Optical Signal) of breastfed 4 month old infant

    The current project will investigate whether nutritional supplements will have beneficial effects on infant brain networks at 4 months of age. We will use the Event-Related Optical Signal (EROS) to non-invasively record brain activity in the infants as they passively listen to sounds (e.g., novel sounds, speech sounds, words, etc.) and watch short video clips of moving objects (e.g., toys, children playing, etc) to look at whether the nutritional supplement influences brain development.

    Brain activity will be assessed at 4 months of age

  • Brain Imaging (Event-Related Optical Signal) of breastfed 9 month old infant

    The current project will investigate whether nutritional supplements will have beneficial effects on infant brain networks at 9 months of age. We will use the Event-Related Optical Signal (EROS) to non-invasively record brain activity in the infants as they passively listen to sounds (e.g., novel sounds, speech sounds, words, etc.) and watch short video clips of moving objects (e.g., toys, children playing, etc) to look at whether the nutritional supplement influences brain development.

    Brain activity will be assessed at 9 months of age

Secondary Outcomes (2)

  • Infant Dry Blood Spot at 4 months

    4 months of age

  • Infant Dry Blood Spot at 9 months

    9 months of age

Study Arms (2)

Postnatal Dietary Supplement

EXPERIMENTAL

Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.

Dietary Supplement: Postnatal Dietary Supplement

Control Supplement

PLACEBO COMPARATOR

Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.

Dietary Supplement: Control Supplement

Interventions

Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.

Postnatal Dietary Supplement
Control SupplementDIETARY_SUPPLEMENT

Placebo Supplement:soybean oil and α-tocopherol (vitamin E)

Control Supplement

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Intention to breast feed for at least the first 3 months
  • years of age or older
  • Willingness to abstain from multi-vitamins or other supplements that contain lutein and vitamin E during the study and take no more than 200 mg of DHA.
  • Normal or corrected-to-normal vision
  • Normal or corrected-to-normal hearing
  • English is the dominant language spoken in the home.

You may not qualify if:

  • and/or early termination:
  • Mother is taking cholesterol medication and/or medication affecting lipid absorption and/or transport.
  • High risk pregnant mothers
  • Macular Pigment Optical Density (MPOD) score greater than 0.6.
  • Preterm birth (less than 37 weeks)
  • Low birth weight (less than 2500 grams, \< 5.5 pounds)
  • Unable or unwilling to continue breast feeding within the first 3 months after birth.
  • Unable or unwilling to continue taking the study supplement within the first 3 months after birth.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beckman Institute

Urbana, Illinois, 61801, United States

RECRUITING

Related Publications (2)

  • Sherry CL, Oliver JS, Renzi LM, Marriage BJ. Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids. J Nutr. 2014 Aug;144(8):1256-63. doi: 10.3945/jn.114.192914. Epub 2014 Jun 4.

    PMID: 24899160BACKGROUND
  • Gratton G, Fabiani M. Fast optical imaging of human brain function. Front Hum Neurosci. 2010 Jun 23;4:52. doi: 10.3389/fnhum.2010.00052. eCollection 2010.

    PMID: 20631845BACKGROUND

Study Officials

  • Gabriele Gratton, Ph.D., M.D.

    University of Illinois at Chicago

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrew Dinsmoor, B.S.

CONTACT

Kathy Low, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2015

First Posted

May 29, 2015

Study Start

February 1, 2015

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

May 4, 2017

Record last verified: 2017-05

Locations